中商官網
數據庫
前沿報告庫
Global Human Respiratory Syncytial Virus Drugs Market 2018 Forecast to 2023
Human respiratory syncytial virus?(HRSV) is a?syncytial?virus?that causes?respiratory tract?infections. It is a major cause of?lower respiratory tract infections?and hospital visits during infancy and childhood. A?prophylactic?medication,?palivizumab, can be employed to prevent HRSV in?preterm?(under 35 weeks gestation) infants, infants with certain?congenital heart defects?(CHD) or?bronchopulmonary dysplasia?(BPD), and infants with?congenital?malformations of the?airway.?Treatment?is limited to supportive care, including?oxygen therapy?and more advanced breathing support with?CPAP?or?nasal high flow oxygen.Scope of the Report:
This report focuses on the Human Respiratory Syncytial Virus Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
One trend in the market is emergence of new entrants likely to change market dynamics. The growing demand for novel products for the treatment of RSV has fueled the emergence of new entrants that are likely to change the market dynamics during the forecast period.?
The active participation of emerging economies toward research and development will drive the growth prospects for the market during the forecast period. The increasing R&D activities in emerging economies for RSV infection and its causes will fuel the development of novel drugs. One of the major factors responsible for the market’s growth is the rising amount of patented therapies for RSV treatment that result in substantial R&D activities from various big pharma companies and research institutes. For instance, in June 2016, the Lancet Respiratory Medicine reported that RSV was the most commonly detected pathogen linked with pneumonia among children in South Africa. Such new findings will increase the scope of anti-RSV drugs in new applications, such as pneumonia.
ROW accounted for the maximum market share during 2017 and continue to dominate the market for the next few years. One of the major factors responsible for the market’s growth in the region is the growing incidence of RSV infections in ROW, including the BRIC nations.
The worldwide market for Human Respiratory Syncytial Virus Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.Market Segment by Manufacturers, this report covers
AstraZeneca
AbbVie
GSK
Teva PharmaceuticalMarket Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)Market Segment by Type, covers
Approved Drugs
Off-Label DrugsMarket Segment by Applications, can be divided into
Clinical Diagnostic
Laboratories Physicians' Office
Laboratories HospitalsThere are 15 Chapters to deeply display the global Human Respiratory Syncytial Virus Drugs market.
Chapter 1, to describe Human Respiratory Syncytial Virus Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Human Respiratory Syncytial Virus Drugs, with sales, revenue, and price of Human Respiratory Syncytial Virus Drugs, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Human Respiratory Syncytial Virus Drugs, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Human Respiratory Syncytial Virus Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Human Respiratory Syncytial Virus Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
?本報告所有內容受法律保護，中華人民共和國涉外調查許可證：國統涉外證字第1454號。 本報告由中商產業研究院出品，報告版權歸中商產業研究院所有。本報告是中商產業研究院的研究與統計成果，報告為有償提供給購買報告的客戶內部使用。未獲得中商產業研究院書面授權，任何網站或媒體不得轉載或引用，否則中商產業研究院有權依法追究其法律責任。如需訂閱研究報告，請直接聯系本網站，以便獲得全程優質完善服務。 本報告目錄與內容系中商產業研究院原創，未經本公司事先書面許可，拒絕任何方式復制、轉載。 在此，我們誠意向您推薦鑒別咨詢公司實力的主要方法。
2024年5月14日，宜賓市經濟和信息局在宜賓主持召開了《宜賓光伏產業高質量發展規劃》（以下簡稱《規劃》）...
2024年5月14日，宜賓市經濟和信息局在宜賓主持召開了《宜賓光伏產業高質量發展規劃》（以下簡稱《規劃》）...
查看詳情
5月8日，貴陽市觀山湖區2024年“觀圖學苑”招商專題開放課堂暨觀山湖區干部“強省會”能力素質提升專題講座...
5月8日，貴陽市觀山湖區2024年“觀圖學苑”招商專題開放課堂暨觀山湖區干部“強省會”能力素質提升專題講座...
查看詳情
4月25日，湖南省東安縣委副書記、縣長蔣華一行蒞臨我院考察交流，會上蔣縣長對我院編制的《東安縣熱能綜合...
4月25日，湖南省東安縣委副書記、縣長蔣華一行蒞臨我院考察交流，會上蔣縣長對我院編制的《東安縣熱能綜合...
查看詳情
4月23日，中共畢節委組織部、畢節市投資促進局在畢節市委黨校舉辦全市產業大招商專題培訓會。培訓會上，中...
4月23日，中共畢節委組織部、畢節市投資促進局在畢節市委黨校舉辦全市產業大招商專題培訓會。培訓會上，中...
查看詳情
4月15日，新疆維吾爾自治區哈密市人民政府黨組成員、副市長一行李建勇蒞臨我院考察指導，會上李市長介紹了...
4月15日，新疆維吾爾自治區哈密市人民政府黨組成員、副市長一行李建勇蒞臨我院考察指導，會上李市長介紹了...
查看詳情
4月9日，甘肅省工業和信息化廳副廳長王永慶一行蒞臨我院考察指導，會上王廳長介紹了甘肅省的產業基礎及現狀...
4月9日，甘肅省工業和信息化廳副廳長王永慶一行蒞臨我院考察指導，會上王廳長介紹了甘肅省的產業基礎及現狀...
查看詳情
4月2日至3日，貴州省商務廳在貴陽市舉辦2024年全省商務系統項目專題培訓會。培訓會上，中商情報網聯合創始...
4月2日至3日，貴州省商務廳在貴陽市舉辦2024年全省商務系統項目專題培訓會。培訓會上，中商情報網聯合創始...
查看詳情
3月19日，貴州省商務廳組織召開《2024 年貴州省外資工作會暨外商投資業務培訓會》。培訓會上，我院項目老師...
3月19日，貴州省商務廳組織召開《2024 年貴州省外資工作會暨外商投資業務培訓會》。培訓會上，我院項目老師...
查看詳情
立即購買
專家咨詢
下載訂購表
word下載
按需定制
簡繁轉換
在線咨詢
